Table 2.
Effects of topiramate on cognition in normal controls.
| Study | Dose of TPM (mg/day) | n | Time on TPM (weeks) | Cognitive AEs from TPM |
|---|---|---|---|---|
| Martin et al. [1999] | 5.7 mg/kg | TPM = 6 | 4 | Psychomotor speed, verbal memory |
| LTG = 5 | ||||
| GBP = 6 | ||||
| Meador et al. [2005] | 300 | TPM = 37 | 8 | Attention/vigilance, memory, naming and verbal fluency, cognitive/motor speed |
| LTG = 38 | ||||
| Salinsky et al. [2005] | 200–400 | TPM = 15 | 12 | Psychomotor speed, verbal contextual memory, consistency of word recall, letter fluency |
| GBP = 16 | ||||
| Placebo = 8 | ||||
| Werz et al. [2006] | 300 | TPM = 37 | 12 | Attention/vigilance, and verbal memory, naming and verbal fluency, and psychomotor speed |
| LTG = 37 | ||||
| (cross-over) | ||||
| Loring et al. [2011]* | 64 | 76 | 24 | Dose dependent, clinically significant deficits, beginning at the 96 mg/day dose. At highest dose, deficits in visual and verbal memory, naming, and reaction speed |
| 96 | 75 | |||
| 192 | 76 | |||
| 384 | 78 | |||
| Placebo | 75 |
*
Cognitively normal obese population. AE, adverse event; GBP, gabapentin; LTG, lamotrigine; TPM, topiramate.